Biofrontera Stock Performance
| BFRI Stock | USD 0.83 0.01 1.49% |
The firm shows a Beta (market volatility) of 2.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biofrontera will likely underperform. At this point, Biofrontera has a negative expected return of -0.0892%. Please make sure to confirm Biofrontera's treynor ratio, as well as the relationship between the daily balance of power and price action indicator , to decide if Biofrontera performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biofrontera has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Biofrontera is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Last Split Factor 1:20 | Last Split Date 2023-07-05 |
1 | Is Biofrontera Inc. stock nearing a technical breakout - Long Setup Weekly Top Performers Watchlists - newser.com | 10/31/2025 |
2 | Biofrontera outlines Q4 2025 revenue growth and anticipates FDA submission for expanded Ameluz indications | 11/13/2025 |
3 | Why Biofrontera Inc. stock is favored by hedge funds - Market Performance Recap Breakout Confirmation Alerts - newser.com | 11/18/2025 |
4 | Is Biofrontera Inc Equity Warrant a good long term investment - Healthcare Stock Analysis Stocks With 200 percent Upside Potential - earlytimes.in | 11/21/2025 |
5 | BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025 - TradingView | 11/28/2025 |
6 | Last Patient Completes Biofronteras Phase 1 Pharmacokinetics Study of Ameluz for Treatment of Actinic Keratoses on the Trunk and Extremities | 12/04/2025 |
7 | Biofrontera Inc. Completes Transfer of Ameluz and RhodoLED FDA approval and Associated Intellectual Property Portfolio | 12/18/2025 |
8 | Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones | 01/08/2026 |
9 | Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between 17.0 Million and 17.5 Million, Representing Approximately 35 percent Year-Ove... | 01/13/2026 |
| Begin Period Cash Flow | 1.5 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Relative Risk vs. Return Landscape
If you would invest 99.00 in Biofrontera on October 18, 2025 and sell it today you would lose (15.00) from holding Biofrontera or give up 15.15% of portfolio value over 90 days. Biofrontera is currently does not generate positive expected returns and assumes 6.1208% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Biofrontera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biofrontera Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biofrontera, and traders can use it to determine the average amount a Biofrontera's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0146
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BFRI |
Based on monthly moving average Biofrontera is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biofrontera by adding Biofrontera to a well-diversified portfolio.
Biofrontera Fundamentals Growth
Biofrontera Stock prices reflect investors' perceptions of the future prospects and financial health of Biofrontera, and Biofrontera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biofrontera Stock performance.
| Return On Equity | -11.92 | ||||
| Return On Asset | -0.65 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0.90) % | ||||
| Current Valuation | 10.88 M | ||||
| Shares Outstanding | 11.65 M | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 0.25 X | ||||
| Revenue | 37.3 M | ||||
| Gross Profit | 23.94 M | ||||
| EBITDA | (14.44 M) | ||||
| Net Income | (17.76 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | (10.27 M) | ||||
| Earnings Per Share | (1.50) X | ||||
| Market Capitalization | 9.43 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (117.41 M) | ||||
| Working Capital | 8.68 M | ||||
About Biofrontera Performance
By evaluating Biofrontera's fundamental ratios, stakeholders can gain valuable insights into Biofrontera's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biofrontera has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biofrontera has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 149.93 | 229.60 | |
| Return On Tangible Assets | (0.93) | (0.97) | |
| Return On Capital Employed | (1.96) | (2.06) | |
| Return On Assets | (0.92) | (0.97) | |
| Return On Equity | (4.61) | (4.84) |
Things to note about Biofrontera performance evaluation
Checking the ongoing alerts about Biofrontera for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biofrontera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biofrontera generated a negative expected return over the last 90 days | |
| Biofrontera has high historical volatility and very poor performance | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 23.94 M. | |
| Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between 17.0 Million and 17.5 Million, Representing Approximately 35 percent Year-Over-Year Growth |
- Analyzing Biofrontera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biofrontera's stock is overvalued or undervalued compared to its peers.
- Examining Biofrontera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biofrontera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biofrontera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biofrontera's stock. These opinions can provide insight into Biofrontera's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |